See more : Universal Star (Holdings) Limited (2346.HK) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCyte Biotech, Inc. (PMCB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCyte Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- UFP Industries, Inc. (UFPI) Income Statement Analysis – Financial Results
- Reddit, Inc. (RDDT) Income Statement Analysis – Financial Results
- Dubber Corporation Limited (DUBRF) Income Statement Analysis – Financial Results
- GrafTech International Ltd. (EAF) Income Statement Analysis – Financial Results
- Bairong Inc. (6608.HK) Income Statement Analysis – Financial Results
PharmaCyte Biotech, Inc. (PMCB)
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.16K | 66.56K | 126.00K | 262.93K | 653.13K | 1.19M | 1.17M | 537.04K | 86.37K | 2.38K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.62K | 19.38K | 32.10K | 228.66K | 427.41K | 266.20K | 171.01K | 0.00 | 41.40K | 780.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K | 47.18K | 93.89K | 34.27K | 225.72K | 923.75K | 998.65K | 537.04K | 44.97K | 1.60K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.89% | 70.88% | 74.52% | 13.03% | 34.56% | 77.63% | 85.38% | 100.00% | 52.07% | 67.27% | 0.00% | 0.00% |
| Research & Development | 407.43K | 468.54K | 690.94K | 916.25K | 301.22K | 460.05K | 2.00M | 1.18M | 1.41M | 3.48M | 323.50 | 0.00 | 0.00 | 9.21K | 492.46K | 473.51K | 412.88K | 133.84K | 119.01K | 1.11M | 1.41M | 0.00 | 0.00 |
| General & Administrative | 4.79M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 9.99M | 18.11M | 1.58M | 1.99M | 462.22K | 1.24M | 5.20M | 0.00 | 0.00 | 6.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 230.50K | 872.20K | 106.41K | 11.15K | 10.83K | 411.72K | 594.34K | 0.00 | 0.00 | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.12M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 10.22M | 18.98M | 1.69M | 2.00M | 473.05K | 1.65M | 5.79M | 4.26M | 4.47M | 7.75M | 3.10M | 313.95K | 32.13K | 0.00 |
| Other Expenses | 0.00 | 202.00K | -4.28K | -1.19K | -40.00 | 33.40K | 152.59K | 2.52M | 10.54K | 3.34M | -5.90M | 2.59K | 1.22M | 103.90K | 0.00 | 4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.85K |
| Operating Expenses | 8.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.69M | 2.00M | 482.25K | 2.14M | 6.27M | 4.67M | 4.61M | 7.87M | 4.21M | 1.72M | 32.13K | 29.85K |
| Cost & Expenses | 6.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.70M | 2.02M | 514.36K | 2.37M | 6.70M | 4.94M | 4.78M | 7.87M | 4.25M | 1.72M | 32.13K | 29.85K |
| Interest Income | 3.40M | 1.94M | 157.65K | 3.05 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 0.00 | 0.00 | 0.00 | 0.00 | 14.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 509.00 | 3.05K | 453.00 | 0.00 | 0.00 | 1.54K | 1.19K | 4.94K | 21.05K | 154.42K | 241.25K | 171.66K | 292.56K | 27.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 492.05K | -5.89M | 2.59K | 24.66K | 40.69K | 114.91K | 28.83K | 6.38K | 1.35K | 488.00 | 23.26K | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -3.83M | 0.00 | 0.00 | -4.44M | 0.00 | -9.92M | -27.23M | -1.68M | -1.63M | -388.36K | -2.11M | -5.99M | -3.78M | -3.61M | -7.33M | -1.72M | -1.73M | -32.13K | -29.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,830.35% | -3,328.88% | 388.91% | 607.14% | -922.67% | -308.99% | -308.83% | -1,049.52% | -4,810.34% | -72,213.26% | 0.00% | 0.00% |
| Operating Income | -6.52M | -6.46M | -4.39M | -3.62M | -3.83M | -4.10M | -6.98M | -4.44M | -6.07M | -13.70M | -18.98M | -1.68M | -1.95M | -388.36K | -2.11M | -6.04M | -3.75M | -3.61M | -7.34M | -4.16M | -1.72M | -32.13K | -29.85K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,851.65% | -2,928.55% | -308.23% | -802.09% | -925.09% | -315.07% | -308.42% | -1,365.85% | -4,819.57% | -72,213.26% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.85M | 2.14M | 152.85K | 71.75K | -493.00 | 33.40K | 152.59K | -1.54K | 9.35K | 2.84M | -8.27M | 86.26K | 49.87K | -837.69K | -3.88M | 471.00 | -42.72K | -6.79K | -1.76M | -114.04K | 1.73M | 0.00 | 0.00 |
| Income Before Tax | 333.76K | -4.32M | -4.24M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.66M | -1.23M | -5.70M | -6.03M | -3.82M | -3.60M | -9.03M | -4.15M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,491.16% | -973.08% | -2,167.62% | -923.10% | -320.62% | -307.90% | -1,682.09% | -4,801.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -153.36K | 3.05K | 453.00 | -33.40K | -152.59K | -4.44K | -4.88K | 4.94K | 19.96K | 154.42K | -49.87K | 1.01M | 3.88M | -471.00 | 42.72K | 6.79K | 2.05M | 114.04K | 1.72M | 32.13K | 29.85K |
| Net Income | 333.76K | -4.32M | -4.09M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.90M | -1.40M | -5.99M | -6.04M | -3.79M | -3.61M | -9.39M | -4.28M | -1.72M | -32.13K | -29.85K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,853.62% | -1,109.32% | -2,278.89% | -925.02% | -318.66% | -309.00% | -1,747.61% | -4,951.60% | -72,375.79% | 0.00% | 0.00% |
| EPS | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.89 | -12.09 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| EPS Diluted | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.88 | -12.08 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| Weighted Avg Shares Out | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 645.76K | 563.54K | 501.60K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
| Weighted Avg Shares Out (Dil) | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 646.08K | 563.82K | 501.85K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket
PharmaCyte Biotech (PMCB) stock is taking off Wednesday and there are a few things that potential investors need to know about the company. The post PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket appeared first on...
PharmaCyte Biotech Shares Increase Over 20% Pre-Market: Why It Happened
The shares of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) increased by over 20% pre-market. This is why it happened.
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released a statement from Kenneth L. Waggoner, the Chief...
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #BigBoardStock--PharmaCyte releases statement on Nasdaq uplisting and current business focus.
PMCB Stock: 2 Big Reasons PharmaCyte Biotech Is Soaring 70% Today
Today, two key catalysts are taking PMCB stock higher, as investors seem to like the positioning of biotech PharmaCyte. The post PMCB Stock: 2 Big Reasons PharmaCyte Biotech Is Soaring 70% Today appeared first on InvestorPlace.
PharmaCyte Biotech Shares Increase Over 94% Intraday: Why It Happened
The shares of PharmaCyte Biotech, Inc. (NASDAQ: PMCB) increased by over 94% during intraday trading. This is why it happened.
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the closing of its previously announced underwritten public...
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #BigBoardStock--PharmaCyte Biotech announces closing of its public offering of approximately $15 million.
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #NASDAQ--PharmaCyte Biotech announces uplist date to NASDAQ and pricing of $15 million public offering.
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company’s common stock is expected to...
Source: https://incomestatements.info
Category: Stock Reports